证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022008 | --- | --- | |------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 投资者关系活动 | 特定对象调研 分析师会议 媒体采访 业绩说明会 | | 类别 参与单位名称及 人员姓名 | 新闻发布会 路演活动 现场参观 其他 君奇资本（王井双）、小忠资本（梁辛）、高铂投资（周建芳）、 华夏嘉实（童进）、正闻投资（朱明中）、恒泰投资（林秋杏）、 平安银行深分投行（张登惠）、个人投资者（赖泽辉、杜东东、 金辉） | | 时间 | ...

Group 1: Company Performance and Market Position - The company's stock price has halved since its peak, raising concerns about its market value and recognition [1][2] - The company aims to enhance performance through increased R&D in sterilization processes and expanding into new application fields [1][2] - The company has achieved revenue and profit growth despite the pandemic, attributed to increased market development and innovation [3][4] Group 2: Strategic Development and Future Plans - The company will continue to focus on "irradiation technology services as the mainstay, with multiple technical methods and diversified industry extensions" [1][6] - Key strategies include enhancing R&D efforts, optimizing investment layouts, and expanding service areas to improve marketing quality [6] - The company is exploring the potential for irradiation technology to disinfect cold chain products and packaging, although practical applications are still under research [5][6] Group 3: Regulatory and Market Challenges - The company is actively applying for recognition as a "specialized, refined, distinctive, and innovative" enterprise in line with government policies [1][2] - The company has been recognized as a key producer of pandemic-related materials and has received accolades from government bodies [2][4] - The company faces challenges in ensuring operational safety and cost-effectiveness in potential new applications for virus disinfection [5][6] Group 4: Competitive Landscape - The company is one of the earliest adopters of industrialized irradiation technology in China and has established itself as a leader in the industry [3][6] - It has the highest cobalt source activity and the most comprehensive network in the irradiation technology service sector in China [6] - The company is positioned favorably in the international market for irradiation sterilization services [6]

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022002 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022003 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022001 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022005 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他（网络会议） | | 参与单位名称及 人员姓名 | 华西证券（戚舒扬） | | 时间 | 2022 年 6 月 2 日下午 16:00—17:00 | | 地点 | 中金辐照会议室 | | 上市公司接待人 员姓名 | 副总经理：于梅 董事会秘书：杨先刚 证券事务代表：曹婷 | | | 1 、医疗保健和食品灭菌行业成长性驱动力在什么地方？ | | | 答：公司主要利用钴 -60 以及电子加速器为客户提供医疗 | | | 保健产品、食品、药品、日用品、包装材料等产品的辐照灭菌 服务， ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 投资者关系活动 类别 | 编号： 2022007 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他（ 2022 深 圳辖区上市公司投资者网上集体接待日活动） | | 参与单位名称及 人员姓名 | 通过"全景路演"网站远程参与集体接待日活动的广大投资者 | | 时间 | 2022 年 11 月 9 日下午 16:30—17:30 | | 地点 | "全景路演"网站（ http://rs.p5w.net ） | | 上市公司接待人 员姓名 | 总会计师张 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥88,841,696.65, representing a 7.69% increase year-over-year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥34,266,430.17, up 19.94% compared to the same period last year[5]. - The basic earnings per share for Q3 2022 was ¥0.1298, reflecting a 19.96% increase year-over-year[5]. - Total operating revenue for Q3 2022 was ¥252,309,741.11, an increase of 9.8% from ¥229,842,284.49 in the same period last year[18]. - Operating profit for Q3 2022 reached ¥114,970,172.21, up 16.8% from ¥98,499,484.91 in Q3 2021[18]. - Net profit attributable to shareholders of the parent company was ¥93,909,975.51, representing a 15.5% increase compared to ¥81,372,705.04 in the previous year[19]. - Total profit for Q3 2022 was ¥114,999,930.39, an increase of 16.9% from ¥98,294,966.24 in the same period last year[18]. Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥1,081,407,082.95, an increase of 8.01% from the end of the previous year[5]. - Accounts receivable increased by 97.91% compared to the end of the previous year, attributed to enhanced market development efforts[8]. - Prepaid accounts increased by 865.38% compared to the end of the previous year, mainly due to increased advance payments to suppliers[8]. - The total current liabilities increased to CNY 40,050,650.06 from CNY 29,207,276.75, representing an increase of approximately 37.0%[16]. - The company's total equity reached CNY 946,011,618.16, up from CNY 877,004,256.30, marking an increase of about 7.9%[16]. - The company's retained earnings increased to CNY 352,123,281.49 from CNY 292,063,578.23, reflecting a growth of approximately 20.6%[16]. - The company reported a significant decrease in accounts payable, which fell to CNY 4,783,461.77 from CNY 10,932,823.36, a reduction of about 56.2%[16]. - The company’s non-current liabilities totaled CNY 95,344,814.73, slightly up from CNY 95,023,989.52, indicating a marginal increase[16]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥152,445,638.16, down 7.81% compared to the previous year[5]. - Cash flow from operating activities was ¥152,445,638.16, down 7.7% from ¥165,362,246.87 in Q3 2021[21]. - The company reported a net cash outflow from investing activities of ¥60,426,828.52, compared to a net outflow of ¥38,914,024.11 in the previous year[22]. - The company experienced a decrease in cash flow from financing activities, with a net outflow of ¥26,141,278.86 compared to a net inflow of ¥132,421,628.25 in Q3 2021[22]. - Cash and cash equivalents at the end of the period totaled ¥381,342,399.31, an increase from ¥297,006,540.87 at the end of Q3 2021[22]. - The company's cash and cash equivalents increased to CNY 381,342,399.31 from CNY 315,464,868.53, reflecting a growth of approximately 20.9%[15]. Expenses and Tax - The company reported a 36.26% increase in income tax expenses year-to-date, driven by increased revenue and profit[9]. - Non-operating income for the year-to-date period decreased by 81.70% compared to the previous year, primarily due to reduced asset disposal gains from subsidiaries[9]. - Research and development expenses increased to ¥15,577,565.53, up 25.3% from ¥12,471,888.52 in the same quarter last year[18]. Government Support and Investments - The company received government subsidies amounting to ¥1,058,099.72 in Q3 2022, contributing to its non-recurring gains[6]. - The company has ongoing investments in construction projects, with construction in progress valued at CNY 63,757,185.53, up from CNY 29,756,359.35[15]. Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in the current report[14].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥163,468,044.46, representing a 10.94% increase compared to ¥147,347,563.20 in the same period last year[20]. - The net profit attributable to shareholders was ¥59,643,545.34, up 12.95% from ¥52,804,172.82 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥58,894,605.03, reflecting a significant increase of 22.94% compared to ¥47,905,659.83 in the previous year[20]. - The net cash flow from operating activities decreased by 17.53% to ¥98,103,005.87 from ¥118,958,590.21 in the same period last year[20]. - Total assets at the end of the reporting period were ¥1,039,787,532.72, a 3.85% increase from ¥1,001,235,522.57 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 3.93% to ¥878,796,762.28 from ¥845,553,406.64 at the end of the previous year[20]. - The basic earnings per share were ¥0.2259, a slight decrease of 1.18% from ¥0.2286 in the same period last year[20]. - The weighted average return on equity was 6.85%, down from 7.71% in the previous year[20]. - The company reported a steady increase in revenue and profit due to the rising demand for sterilization services in the healthcare sector, driven by the ongoing pandemic[51]. Business Operations - The main business of the company is irradiation technology services, primarily providing sterilization services for healthcare products, food, pharmaceuticals, and packaging materials, which is the main source of revenue and profit[28]. - The company utilizes cobalt-60 and electron beam technology for sterilization, ensuring effective sterilization without contamination or residue, maintaining a sterile state for healthcare products[30]. - The irradiation sterilization services cover various sectors, including healthcare products, food, pharmaceuticals, and packaging materials, with a focus on maintaining product quality and extending shelf life[31][32][33]. - The company has established regional centers in seven major cities, implementing a unified planning and regional operation model to enhance service delivery and market expansion[38]. - The revenue from irradiation technology services has shown an upward trend due to increasing demand driven by economic growth and continuous market development by subsidiaries[40]. - The company emphasizes personalized services tailored to customer specifications, which helps build strong customer loyalty and relationships[40]. - The company’s fixed costs, including depreciation of irradiation equipment, are significant, and profitability increases rapidly as revenue scales up after the initial market development phase[40]. - The procurement model is based on demand, with a strict budget management system in place for purchasing, particularly for cobalt sources used in irradiation services[41]. - The company must obtain various regulatory approvals for the procurement and transportation of radioactive cobalt sources, ensuring compliance with safety and environmental regulations[41]. - The company operates 10 gamma irradiation devices and 1 electron accelerator across 7 regional centers in China, with ongoing projects in Zhejiang and Chengdu to expand capacity[42]. - The company has established a quality management system compliant with international standards, receiving certifications from BSI, TUV, and others, ensuring service quality and compliance with national and international standards[44]. - The company has a stable customer base, primarily large companies with stringent supplier certification processes, leading to consistent and increasing demand for sterilization services[46]. Research and Development - Research and development investment increased by 31.45%, reaching approximately ¥9.90 million, up from ¥7.53 million in the previous year[67]. - The company established 30 new R&D projects in the first half of 2022, including the study of dose distribution in electron accelerator irradiation processing[53]. - The company holds a stable core technical team, with no significant changes reported during the reporting period[54]. - The company has developed its own irradiation information management system to enhance operational efficiency and service traceability[45]. - The company is actively promoting new irradiation technologies and applications to enhance market competitiveness and expand its market share[51]. Financial Management - The company plans to distribute a cash dividend of ¥1.50 per 10 shares, totaling approximately ¥39,600,284.55 based on 264,001,897 shares[4]. - The company received government subsidies amounting to ¥871,618.82 during the reporting period, contributing to its financial performance[24]. - The company has implemented a centralized management model for cobalt source procurement, which helps reduce costs and improve resource allocation efficiency[63]. - The company reported a significant increase in financial expenses, with a decrease of 431.62% due to no borrowings and increased interest income from deposits[67]. - The company has a comprehensive quality management system that complies with multiple international standards, ensuring effective quality control and management[56]. Market Strategy - The company plans to enhance its market development efforts, particularly in new fields of irradiation technology applications and disinfection supply services, to further improve operational performance[91]. - The company aims to expand its customer base for irradiation services and increase new profit growth points amid ongoing pandemic challenges[90]. - The company has expanded its irradiation service network across key economic regions, including the Yangtze River Economic Belt and the Guangdong-Hong Kong-Macao Greater Bay Area[59]. - The company is committed to enhancing its core competitiveness and market expansion strategies in response to industry trends[91]. Shareholder and Compliance - The company has committed to protecting shareholder rights and ensuring equal treatment for all shareholders[104]. - The company will ensure compliance with any regulatory restrictions on share circulation[110]. - The company has fulfilled its commitments regarding share transfers as of April 2022[110]. - The company will disclose specific reasons for any failure to fulfill commitments in a timely manner[127]. - The company commits to compensating investors for losses caused by false statements or omissions in the public offering documents[127]. - The company will accept supervision from regulatory authorities to ensure compliance with public commitments[127]. Social Responsibility - The company actively engages in social responsibility initiatives, including blood donation activities and purchasing unsold agricultural products to support impoverished areas[106]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company’s subsidiaries comply with national environmental protection standards and regulations[103].

Financial Performance - The company's operating revenue for 2021 was CNY 309,072,018.55, representing a 20.75% increase compared to CNY 255,963,220.94 in 2020[17]. - The net profit attributable to shareholders for 2021 was CNY 87,119,688.54, a 41.57% increase from CNY 61,538,234.33 in 2020[17]. - The net profit after deducting non-recurring gains and losses was CNY 80,371,540.97, up 34.76% from CNY 59,640,775.03 in 2020[17]. - The net cash flow from operating activities was CNY 175,550,139.58, an increase of 24.93% compared to CNY 140,517,444.56 in 2020[17]. - The total assets at the end of 2021 reached CNY 1,001,235,522.57, a 37.14% increase from CNY 730,072,786.50 at the end of 2020[17]. - The net assets attributable to shareholders at the end of 2021 were CNY 845,553,406.64, reflecting a 40.65% increase from CNY 601,175,030.08 at the end of 2020[17]. - The basic earnings per share for 2021 were CNY 0.3520, a 13.26% increase from CNY 0.3108 in 2020[17]. - The weighted average return on equity for 2021 was 11.27%, up from 9.78% in 2020[17]. Revenue Sources and Growth - The company's total revenue for the four quarters was approximately 309.07 million, with the highest revenue in Q3 at 82.49 million, representing a 20% increase from Q1[19]. - The revenue from irradiation technology services accounted for 92.22% of total revenue, amounting to ¥285,019,312.30, with a year-on-year growth of 22.25%[73]. - The main source of revenue is from irradiation technology services, with an upward trend in profitability due to increasing demand and market expansion[40]. - The company is focused on expanding its irradiation sterilization services for medical products, food, and packaging materials, which are its main revenue sources[29]. Research and Development - Research and development expenses amounted to CNY 21,089,583.24, an increase of 18.23% year-on-year, indicating a rise in R&D investment[68]. - The company launched 34 new technology research projects in 2021, including automatic systems for gamma irradiation facilities, and obtained 2 invention patents and 26 utility model patents[54]. - The company added 26 new technology research and development patents and 7 software copyrights in 2021, bringing the total to 179 patents and 65 copyrights[71]. - The number of R&D personnel increased by 19.13% from 115 in 2020 to 137 in 2021, with R&D personnel now accounting for 24.29% of the total workforce[88]. Operational Efficiency - The operational efficiency improved with a 9.3 million CNY increase in labor productivity per person compared to the previous year[70]. - The company has implemented an information management system to improve operational efficiency and service traceability[45]. - The company has established a quality management system compliant with international standards, ensuring service quality and customer satisfaction[44]. - The company has maintained stable operational performance despite local pandemic outbreaks, providing uninterrupted irradiation sterilization services for medical products[51]. Market Expansion and Strategy - The company is actively seeking new growth opportunities through both organic growth and external expansion, aiming to increase its market presence and investment layout[115]. - The company has expanded its irradiation service network across key economic regions, enhancing its market presence and reducing single-market risks[60]. - The company is developing a project in Zhejiang for sterilizing 300,000 cubic meters of medical devices annually, indicating market expansion efforts[43]. - The company achieved a significant revenue increase in the Central China region, with a growth rate of 58.70%[74]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[128]. - The company maintains independent operations in terms of assets, personnel, finance, organization, and business, with no asset occupation by the controlling shareholder[132][133]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating a clean compliance record[160]. - The company has a comprehensive strategy for talent management, focusing on performance evaluation and compensation linked to company performance[161]. Shareholder Engagement - The company held two shareholder meetings during the reporting period, both conducted with a combination of on-site and online voting, ensuring all resolutions were passed legally and effectively[124]. - A total of 13 questions were raised by investors during the online earnings briefing, focusing on operational performance, pandemic impacts, quality advantages, and business development[120]. - The annual shareholders meeting had a participation rate of 69.58% on May 18, 2021[138]. - The first extraordinary shareholders meeting had a participation rate of 60.00% on December 29, 2021[138]. Corporate Social Responsibility - The company actively fulfills its corporate social responsibility by promoting safety, health, and environmental protection[188]. - The company provided sterilization services for epidemic prevention products, generating approximately 900 million yuan in revenue for the year 2021[192]. - The company received recognition from the National Atomic Energy Agency and industry associations for its outstanding contributions during the pandemic[192]. - The company actively participated in social responsibility initiatives, including poverty alleviation and support for children in need[193]. Future Outlook - The company aims to achieve an annual revenue target of 322.02 million and a net profit target of 90.10 million for 2022, indicating a growth strategy focused on expanding market share[115]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues to reach approximately 1.65 billion RMB[150]. - The company is positioned to benefit from favorable industry policies and a growing market demand for non-power nuclear technology applications, which are recognized as strategic emerging industries[112][114].